This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk04: Greetings and welcome to the Avenger first quarter 2024 results call. At this time all participants are on a listen only mode and a question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference please press star zero on your telephone keypad. Please note this call is being recorded. I'm going to turn the conference over to your host, Mr. Matt Kreps. Sir, you may begin.
spk02: Thank you, and thank you all for participating in today's call. I'd like to welcome you to Avenger's first quarter 2024 conference call. Joining us today are Avenger's CEO, Jeff Zawinski, and Principal Financial Officer, Nabil Spinetti. Earlier today, Avenger released financial results for the quarter ended March 31, 2024. A copy of the release is posted on the Avenger website under Investor Relations. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that are not statements of historical fact should be deemed to be forward-looking statements. All forward-looking statements including without limitation our future financial expectations and expected timing for commercial launch of products and funds within the FDA, are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, Please see our Form 10-K and 10-Q filings with the Securities and Exchange Commission. Avenger disclaims any intention or obligation except as required by law to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. Today's presentation will include reference to non-GAAP financial measures, such as adjusted EBITDA, reconciliation of these non-GAAP financial measures to the most comparable GAAP financial measures is available within the earnings release, which can be found on Avenger's website. And with that, I'd like to now turn the call over to Jeff. Thank you.
spk01: Thank you, Matt. Good afternoon, and thank you all for joining us. Along with continued progress in our peripheral business, we had two exciting events in the first quarter that will provide significant new opportunities for Avenger as we move our company forward. In March, we announced a strategic partnership with Xilox Tunbridge, which opens a pathway for the introduction of our image-guided devices to the vast and growing greater China market. During the first quarter, we also made exciting progress in the development of our first coronary product, initiating Phase III verification and validation studies for our proprietary CTO crossing device, as we prepare for filing an IDE submission with the FDA later this year. Starting with our new strategic partnership, Xylox Tunbridge is a fully integrated medical device company and a leader in the peripheral vascular and neurovascular markets in China. Since their founding in 2012, Xylox has developed and launched 36 products into the greater China interventional markets. They maintain a state-of-the-art manufacturing facility at their headquarters in Hangzhou, China, and are certified to the ISO 13485-2016 International Quality Standard. Under the terms of an equity financing agreement, Xilox will invest up to $15 million in New Avenger through the purchase of preferred and common stock in two tranches. The first $7.5 million tranche was funded in March. A second tranche, $7.5 million equity investment, will be funded upon achieving key milestones, including successfully registering Xilox as a manufacturer of Avenger's products with the US FDA and Avenger achieving $10 million in aggregate revenue over four consecutive quarters. Under the terms of a license and technology transfer agreement, Xilox has exclusive rights to distribute and manufacture Avenger's proprietary image-guided devices in the Greater China region, including mainland China, Hong Kong, Macau, and Taiwan. We are supporting Xilox in their regulatory process as they prepare for registration of the Avenger products in China. Following regulatory clearance, Avenger will sell products to Xilox for their initial product launch until such time as Xilox has established their own manufacturing capability and gained regulatory authorization for manufacturing Avenger products for the China markets. Sales of Avenger products in the Xilox territory will be royalty bearing to Avenger. With more than 130 employees in sales and marketing and an extensive distribution network, Xilox is extremely well qualified to distribute Avenger products in the greater China region. Once Xilox has established their manufacturing capability and been successfully registered as a manufacturer of AVENGER's products with the US FDA, we will have the option to source finished product from Xilox on a cost-plus basis. We believe this could provide the opportunity for AVENGER to reduce cost of goods sold, improve gross margin, and reduce facility and related overhead expense in the future. Our collaboration with Xilox is off to a great start, and we're excited about the strategic benefits this relationship brings to Avenger, strengthening our balance sheet, providing a pathway to vast new markets, and creating the opportunity to improve our gross margin and cost structure over time. Now turning to our coronary development program. We are very excited about the progress we are making in the development of our first coronary device, an image-guided CTO crossing system based upon our proven technology platform, which we believe provides the opportunity to redefine a large and underserved market. Following an extensive design and development process and multiple rounds of animal studies and cadaver heart studies with KOL physicians expert in coronary CTO crossing and OCT intravascular imaging, We have completed phase two design selection and have advanced our development program to phase three in the product development process. Pending successful completion of the required verification and validation testing, we anticipate being in a position to file an IDE submission with the FDA in the third quarter of this year to allow for initiation of a clinical study following approval. Crossing chronic total occlusions in the coronary arteries can be complex, time-consuming, and have high failure rates. By leveraging our proprietary image-guided technology, we believe we can provide physicians with a superior, simplified, and more predictable solution for crossing coronary CTOs with the need for less radiation exposure and contrast media usage. Our coronary system features a low-profile, four-french catheter design that combines real-time OCT guidance with precise control and steerability to facilitate an antigrade approach, which we expect to significantly reduce procedure times and improve crossing success rates. Like our peripheral catheters, our coronary device incorporates a precise measurement capability to help physicians properly size balloons or stents prior to placement, which is critical for optimal outcomes. We think our solution can accomplish this with less reliance on specialty wires, support catheters, recanalization devices, and reentry devices, while also limiting X-ray radiation exposure and usage of iodine-containing contrast dye, which can pose various health risks. We are confident our combination of onboard image guidance and precise control within the vessel will support a robust safety profile during clinical practice. We believe our coronary CTO crossing device will present a highly compelling economic value proposition. Reducing crossing time, contrast media usage, and the need for certain accessory devices would result in significant cost savings for the hospital system. In addition, our coronary system would not only access existing high value reimbursement codes for CTO crossing, It would also access existing codes for coronary OCT diagnostic imaging immediately upon FDA clearance. We think this makes great sense from both a clinical and business perspective, and we're excited to provide further updates as we advance this revolutionary product to IDE filing later this year. During the first quarter, we also continued to make progress with our peripheral business. Our new sales representatives and clinical specialists have completed their onboarding and are gaining clinical proficiency with our devices as they build their sales pipelines and advance new accounts and users through the sales process. Our new Tiger IST CTO crossing device, launched in the second half of last year, continues to increase market penetration and support the growth of our CTO business. And we continue to gain valuable clinical experience with our new Pantheris LV large vessel latherectomy device as we prepare for commercial expansion later this year. At this point, I'd like to turn the call over to Nabil Spinetti, our principal financial officer and accounting officer, to take us through the financial results, and then I'll return for Q&A. Nabil?
spk00: Thank you, Jeff. Total revenue was $1.9 million for the first quarter of 2024, compared with $1.9 million in the fourth quarter of 2023 and $1.9 million in the first quarter of 2023. Gross margin for the first quarter of 2024 was 18% compared to 20% in the fourth quarter of 2023 and 34% in the first quarter of 2023. The change in gross margin primarily reflects lower production activity during the quarter as we continue to optimize inventory levels while conserving cash expenditures. Operating expenses for the first quarter of 2024 were $5.4 million compared to the $5.0 million in the fourth quarter of 2023 and $4.9 million in the first quarter of 2023. The increase in operating expenses primarily relate to the increase in sales headcount and expenses related to the Xilox Thornbriggs transaction, which Jeff had discussed earlier, and other corporate activities. Net loss and comprehensive loss for the first quarter of 2024 was $5.5 million compared with $5.0 million in the fourth quarter of 2023 and $4.6 million in the first quarter of 2023. Adjusted EBITDA as defined under our non-GAAP financial measures provided in today's press release was a loss of $3.9 million compared to a loss of $4.3 million in the fourth quarter of 2023 and a loss of $3.9 million in the first quarter of 2023. For more information regarding non-GAAP financial measures, please see the non-GAAP financial measures and reconciliation of non-GAAP measures to the nearest GAAP measure provided in the tables in today's press release. Cash and cash equivalents totaled $7.2 million as of March 31st. In March of this year, CRG Partners, the primary holder of Avenger Debt and Preferred Equity, exchange its Series A preferred stock with an aggregate liquidation preference of $61 million for new Series A1 preferred stock with a value of $10 million. The new Series A1 preferred stock is convertible at a conversion price of $3.66 per share and carries no liquidation preference or dividend preference. CRG extended principal payments on Avenger's debt from the first quarter of 2024 to the first quarter of 2027, with interest payments occurring during this time. At this point, I'd like to turn the call back to Jeff for Q&A.
spk01: Thanks, Nabil. We're excited about our new partnership with Xylox Tunbridge and the rapid progress we're making in the development of our first coronary product. We're encouraged by the outstanding clinical outcomes we see physicians deliver with our peripheral devices and cath labs across the country every day, and we appreciate the dedicated efforts of our team as they remain committed to our mission of radically changing the way vascular disease is treated. At this point, we'd be happy to take your questions.
spk04: Thank you. At this time we will be conducting our question and answer session. If you would like to ask a question, please press star 1 on your telephone keypad. A confirmation token will indicate your line is in the queue. You may press star 2 if you would like to remove your question from the queue. And for participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment please while we poll for questions. Thank you. We have a question on the line from Swayamkula Ramakant from HC Wainwright. Your line is live.
spk03: Thank you. Good afternoon, Jeff and Nabil. A couple of quick questions. The first one is on the new partnership that you're talking about with Xylox Stonebridge. So I'd just like to understand, When do you anticipate commercialization of product in China? How long do you think that they would take to get products registered so that they can start commercializing the stuff which you're producing here before they're able to manufacture themselves over there?
spk01: Thanks for the question, RK. So yes, we are... very, very pleased with how quickly and how engaged Xilox is in not only building their internal manufacturing capability, but also developing all of the documentation required to support the registration of our products in China. We actually got a little head start on that as we were finalizing our agreements, and so it is a priority both in their organization as well as our organization. Now, they control the timelines, and there's much out of their control as well, given that the Chinese regulatory system, just like the U.S. FDA, will move at their own pace. However, based on our projections, we expect that it is realistic that registration could be achieved prior to the end of 2025. And we expect that the manufacturing capability at Xilox can come online and be validated within that timeframe as well. So again, a very productive and focused effort that we think can bear fruit in 2025. Okay.
spk03: So as you're waiting for the product to be commercialized in China, You're also talking about product that can be commercialized in Europe. So since you have the CE mark there, is it easier to get started now there? Or how does that work in China?
spk01: I mean, in Germany, sorry. So in Germany, we, as you know, currently market our products under CE Mark, and we also distribute our products in other markets as well. But our primary European market is Germany, given the reimbursement structure and the relationships we have with certain KOL physicians. So we don't see an opportunity for, you know, incremental revenue with our products beyond the growth that our team is focused on driving in Europe. However, there are certain products that Xilox has that have CE marking, which we have the ability to engage with them to see if it would be suitable for us to distribute those products into our existing accounts in Germany. The timeframes on that would not require a new regulatory registration, but we're prioritizing getting them up to speed and their regulatory clearance efforts underway for China and also developing their manufacturing capability, which we see as the larger opportunity.
spk03: Yeah, yeah, understood. And then in terms of what you're doing here in the U.S., regarding the IDE submission, you know, that they're anticipating, especially for the CTO crossing system. In the third quarter, what else needs to get done, you know, for you to submit that application?
spk01: Yes, so, you know, really just the process The basis of an IDE submission would require that you complete your phase three verification validation testing, which would include DVT and DVAL testing. We have a final design, and we're in process on that full suite of biocompatibility testing, having the clinical study design and your initial sites identified, as well as the as well as any GMP animal studies that are required. And so we're in that process now really on all of those things. As you know, we completed design selection at the end of 2023. So we've been into this now for most of this year. and feel like we are in good shape. Obviously, we have to complete all the testing and get the results, the desired results, and that could impact timing. But based on what we know now, we feel like we're in good shape to achieve our objective of filing prior to the end of the third quarter.
spk03: Okay. Fantastic. Then thank you very much. Thanks for taking all my questions.
spk01: Thank you. Thank you, R.K.
spk04: Thank you. As we have no further questions in the queue at this time, I will hand it back to Mr. Sawinski for any closing comments he may have.
spk01: Thank you. And thank you all for joining our call this afternoon. We very much appreciate your interest in our company and look forward to reporting our further progress in the coming quarters. Have a good evening.
spk04: Thank you. This concludes today's call and you may disconnect your lines at this time. And we thank you for your participation.
Disclaimer